Blenrep

News

GSK's Blenrep hopes take a knock as drug fails trial

GSK has great expectations for its BCMA-directed cancer drug Blenrep, but a failed phase 3 trial in relapsed or refractory multiple myeloma has raised doubts about its prospects – and even

News

GSK sees £20bn peak sales potential in late-stage pipeline

GlaxoSmithKline's pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory

Events

Partner Content

BCMA Targeted Therapies Summit

Built with thought leaders from Seattle Genetics, Precision Biosciences and Kite Pharma, the inaugural industry-focused

News

GSK moves further ahead in BCMA with EU okay for Blenrep

GlaxoSmithKline has approval on both sides of the Atlantic for its multiple myeloma drug Blenrep, after getting the nod from the European Commission.

News

FDA approves GSK's Blenrep for advanced multiple myeloma

The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease.

News

CHMP gives nod to GSK’s BCMA drug Blenrep for myeloma

GlaxoSmithKline is closing in on EU approval for its first-in-class BCMA-targeting drug Blenrep, after getting a green light from the EMA’s human medicines committee.

GSK's Blenrep hopes take a knock as drug fails trial

GSK sees £20bn peak sales potential in late-stage pipeline

BCMA Targeted Therapies Summit

GSK moves further ahead in BCMA with EU okay for Blenrep

FDA approves GSK's Blenrep for advanced multiple myeloma

CHMP gives nod to GSK’s BCMA drug Blenrep for myeloma

Major trial launched to explore GLP-1 benefit in dementia

Discover a new era of healthcare panel engagement: Grounded ...

Blenrep

Editor's Picks